Elsilimomab
Elsilimomab (also known as B-E8) is a mouse monoclonal antibody.[1] B-E8 was developed by Diaclone,[2] a French company which produces many mouse monoclonal antibodies.
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | IL-6 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
It (OPR-003) targets (and blocks) Interleukin-6.[3]
It has undergone a number of early stage clinical trials, e.g. for lymphoma and myeloma.[4]
It was used as a template to develop a high-affinity, antagonist, fully human anti-IL-6 mAb 1339.[4]
References
- "WHO Drug Information" (PDF). Archived from the original (PDF) on October 16, 2009.
p11:immunoglobulin G1, anti-(human interleukin 6) (mouse monoclonal B-E8 heavy chain), disulfide with mouse monoclonal B-E8 k-chain, dimer
- "Datasheet B-E8 mAb". Diaclone.
- "First Fully Human Anti-IL6 Antibody Under Development". Genetic Engineering & Biotechnology News. Oct 2006.
- Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, et al. (December 2009). "A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma". Clinical Cancer Research. 15 (23): 7144–52. doi:10.1158/1078-0432.CCR-09-1483. PMC 2787636. PMID 19934301.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.